The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study) by Kageaki Watanabe, MD, Yukio Hosomi, MD, PhD, Katsuhiko Naoki, MD, PhD, Yoshiro Nakahara, MD, PhD, Yoko Tsukita, MD, PhD, Hirotaka Matsumoto, MD, PhD, Kiyotaka Yoh, MD, Yasuhito Fujisaka, MD, PhD, Satoshi Takahashi, MD, PhD, Saori Takata, MD, PhD, Kazuhiro Usui, MD, PhD, Kazuma Kishi, MD, PhD, Go Naka, MD, PhD, Shu Tamano, MSS, Kohei Uemura, PhD, Hideo Kunitoh, MD, PhD

Get full text